SecBot SecBot
SECBOTREPLAY Home › Report › AKBA

AKBA · Akebia Therapeutics and U.S

Akebia Therapeutics, Inc. · 8-K filed Jun 30, 2026 at 08:05 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 30, 2026 at 08:05 ET

Akebia Therapeutics and U.S. Renal Care announced that the VOICE trial (Vafseo vs. ESA in 2,116 dialysis patients) met its predefined stopping criteria at interim analysis with a win odds of 1.16 (p=0.0016), establishing superiority on the composite endpoint of all-cause mortality and hospitalization. The trial was stopped early based on the recommendation of the Independent Data Monitoring Committee, driven by a statistically significant reduction in hospitalizations (IRR 0.90, p<0.05), with no difference in mortality. This is a strong clinical catalyst, the trial validates Vafseo's safety differentiation over ESAs using a three-times-weekly dosing regimen and directly supports Akebia's commercial positioning in the $306M market cap company's sole marketed product.

  • VOICE trial enrolled 2,116 patients; stopped early by IDMC after meeting prespecified superiority stopping criteria.
  • Primary composite endpoint win odds 1.16 (95% CI 1.06–1.28, p=0.0016), establishing non-inferiority and superiority vs. ESA.
  • Hospitalizations per patient-year: 1.11 (Vafseo) vs 1.23 (ESA), incidence rate ratio 0.90 (95% CI 0.824–0.988), p<0.05.
  • Mortality: 8.77% vs 8.78% per 100 patient-years, incidence rate ratio 1.00 (95% CI 0.718–1.391), not statistically significant.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access